| |
Feb 1, 2011 Phase III trial failures..
The therapeutic areas in which the largest proportions of these failures occurred were: cancer (28%); nervous system, which includes neurodegeneration (18%); alimentary and/or metabolism, which includes diabetes and obesity (13%); and anti-infectives (13%).
For full report go to: Nature Reviews« Back |
